Gastroprotective Efficacy of Rebamipide in Patients With Atrial Fibrillation Treated With DOACs

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.

Also called NCT07354230

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 210 participants (enrolled count) (from the registry)
Sponsor
Pirogov Russian National Research Medical University (from the registry)
Registry
  • NCT NCT07354230
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07354230. Randomized; no masking; primary purpose treatment. Start 2022-01-11 (actual); primary completion 2024-09-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Gastroprotective Efficacy of Rebamipide in Patients With Atrial Fibrillation Treated With DOACs
Acronym
REGATA
Condition
Atrial Fibrillation (AF)
Intervention (Drug)
Rebamipide 100mg
Intervention (Drug)
Pantoprazole
Lead sponsor
Pirogov Russian National Research Medical University (class: other)

Record details

Record id
cardio:ct-nct07354230
Content hash
47d39692591ba62a1b25a3601963c28b089fdda90b99d92817032ee7d8e35623